UniQure 的基因疗法 AMT-130 在一项试验中将亨廷顿病的进展减缓了 75%，使库存增加了 230% 以上。 UniQure's gene therapy AMT-130 slowed Huntington’s progression by 75% in a trial, boosting stock over 230%.

周三,UniQure的股票幅超过230%,达到约45.60美元,因为其基因疗法AMT-130在亨廷顿病I/II期试验中达到主和次要终点,显示36个月后疾病进展减缓了75%和功能衰退减少了60%. UniQure's stock jumped over 230% to around $45.60 on Wednesday after its gene therapy AMT-130 met primary and secondary endpoints in a Phase I/II trial for Huntington’s disease, showing a 75% slowing of disease progression at 36 months and a 60% reduction in functional decline. 治疗耐受性良好,运动和认知指标呈现积极趋势,神经退行生物标志物减少. The therapy was well-tolerated, with positive trends in motor and cognitive measures and reduced neurodegeneration biomarkers. 该公司计划于2026年初提交生物许可证申请,并已从海克力士资本公司获得1.75亿美元的非增值贷款,以支持商业准备。 The company plans to file a Biologics License Application in early 2026 and has secured a $175 million non-dilutive loan from Hercules Capital to support commercial readiness.